



Announcement Summary

Entity name

MEDIBANK PRIVATE LIMITED

Date of this announcement

Tuesday April 07, 2026

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
MPLAA	PERFORMANCE RIGHTS	22,184	30/03/2026

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

MEDIBANK PRIVATE LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

47080890259

1.3 ASX issuer code

MPL

1.4 The announcement is

New announcement

1.5 Date of this announcement

7/4/2026



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

MPLAA : PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

30/3/2026

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

No

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

These performance rights (Rights) were granted under Medibank's FY26 Long Term Incentive (FY26 LTI) plan. A summary of the terms of these Rights is set out on pages 61-64 of Medibank's Annual Report 2025: https://www.medibank.com.au/content/dam/retail/about-assets/pdfs/investor-centre/annual-reports/Medibank_AnnualReport2025.pdf noting:

- the 3 year performance period commenced on 1 July 2025;
- the threshold levels for the earnings per share compound annual growth, private health insurance market share growth and brand sentiment performance hurdles are the same as those applying to the Rights granted to Medibank's Chief Executive Officer under the FY26 LTI plan as set out on pages 15-16 of the Medibank's Notice of AGM 2025: https://www.medibank.com.au/content/dam/retail/about-assets/pdfs/investor-centre/annual-general-meeting/Medibank_NoM2025.pdf ; and
- there is no deferral period for any of these Rights which vest.

Any other information the entity wishes to provide about the +securities the subject of this notification

Issue details

Number of +securities

22,184



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
MPL : ORDINARY FULLY PAID	2,754,003,240

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
MPLAA : PERFORMANCE RIGHTS	10,211,972



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

22184

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

No